These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 12648581

  • 1. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
    Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R, Kushima M, Farina A, Kuwano Y, Okai T.
    Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma.
    Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M, Tachikawa T.
    Med Electron Microsc; 2004 Sep; 37(3):188-92. PubMed ID: 15449112
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP.
    Cancer; 1997 Apr 15; 79(8):1587-94. PubMed ID: 9118043
    [Abstract] [Full Text] [Related]

  • 6. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.
    Gynecol Oncol; 2001 Feb 15; 80(2):189-93. PubMed ID: 11161858
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
    Xu B, Hamada S, Kusuki I, Itoh R, Kitawaki J.
    Gynecol Oncol; 2011 Feb 15; 120(2):239-46. PubMed ID: 21130491
    [Abstract] [Full Text] [Related]

  • 9. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb 15; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D, Hirschmann A, Löhrs U, Diebold J.
    Gynecol Oncol; 2006 Dec 15; 103(3):883-7. PubMed ID: 16806438
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S, Bosman FT, Givel JC.
    Eur J Cancer; 2000 May 15; 36(8):1008-15. PubMed ID: 10885605
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A, Sarian LO, Ferracini AC, Costa LBE, Mazzola PG, de Angelo Andrade L, Derchain S.
    Hum Pathol; 2019 Mar 22; 85():72-81. PubMed ID: 30447298
    [Abstract] [Full Text] [Related]

  • 17. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
    Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L.
    Cancer; 2000 Feb 15; 88(4):814-24. PubMed ID: 10679651
    [Abstract] [Full Text] [Related]

  • 18. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ.
    Cancer Res; 1993 Jul 01; 53(13):3103-8. PubMed ID: 8319218
    [Abstract] [Full Text] [Related]

  • 19. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S, Chapman W, McLaughlin J, Andrulis IL.
    Cancer J; 2000 Jul 01; 6(5):302-8. PubMed ID: 11079169
    [Abstract] [Full Text] [Related]

  • 20. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C, Bassiouny D, Lerner-Ellis J, Olkhov-Mitsel E, Ismiil N, Hogen L, Vicus D, Nofech-Mozes S.
    Am J Surg Pathol; 2019 Dec 01; 43(12):1591-1599. PubMed ID: 31335355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.